Shots:
- Aptar Pharma and Aceso Therapeutics have entered into a collaboration to advance ACT-101, an antisense oligonucleotide (ASO) candidate designed to target underlying disease mechanisms of cystic fibrosis (CF)
- Aptar Pharma’s specialist inhalation development services business; Nanopharm will lead formulation development and device assessment activities to support clinical development of ACT-101
- The collaboration combines Nanopharm’s expertise in inhaled and nasal drug product development with Aptar Pharma’s broader scientific capabilities to advance Aceso Therapeutics’ ASO platform
Ref: Aptar | Image: Aptar & Aceso| Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
